Evidence map›Paper›PMID 32857840›Full record

ArticleJournal of the National Cancer Institute2021

Advancing Assessment, Analysis, and Reporting of Safety and Tolerability in Cancer Trials.

Paul G Kluetz, Bellinda L King-Kallimanis, Daniel Suzman, Elaine Chang, Michael M Brave, Chana Weinstock, Vishal Bhatnagar, Julia A Beaver, Meredith K Chuk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  2. Review
  3. Article
  4. Review
  5. Understanding Treatment Tolerability in Older Adults With Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paul G KluetzOncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.
Bellinda L King-KallimanisOncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.ORCID 0000-0001-9418-9374
Daniel SuzmanOncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.
Elaine ChangOncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.ORCID 0000-0001-6255-2853
Michael M BraveOncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.
Chana WeinstockOncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.
Vishal BhatnagarOncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.
Julia A BeaverOncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.
Meredith K ChukOffice of Oncologic Diseases, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.ORCID 0000-0002-5061-3425

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsHumans

Identifiers

PMID32857840
PMCPMC8096361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.